Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.
Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.
Tessa Cigler, MD, MPH, discusses the agents that are improving survival for women with early-stage and metastatic HER2-positive breast cancers.
Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.
Michel Velez, MD, provides perspective on the clinical experience with neratinib in patients with early-stage HER2-positive breast cancer as well as promising data that may lead to an indication in the metastatic setting.
Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.
Health Canada has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab (Herceptin)-based adjuvant therapy.
An application has been submitted to the FDA for neratinib for use in combination with capecitabine for the third-line treatment of patients with HER2-positive metastatic breast cancer.
Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.
Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.